Medical supplies company Embecta beats Q3 estimates, raises FY forecast

Embecta

08/08/2025 11:42

Overview

Embecta Q3 revenue rises 8.4% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q3 beats consensus, reaching $1.12, per LSEG data

Co's adjusted EBITDA of $131 mln exceeds estimates, reflecting strong performance

Outlook

Embecta raises fiscal 2025 revenue outlook to $1,078-$1,085 mln

Company expects adjusted EPS for fiscal 2025 between $2.90 and $2.95

Embecta anticipates adjusted operating margin of 30.75%-31.00% for fiscal 2025

Result Drivers

COMMERCIAL EXECUTION - Embecta attributes Q3 revenue growth to solid commercial execution and timing of customer orders

ERP IMPLEMENTATION - Successful implementation of ERP system and operationalization of distribution centers in India completed a multi-year separation program

PRODUCT EXPANSION - Signed contracts for co-packaging pen needles with potential generic GLP-1 drugs, expanding product portfolio

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$295.50 mln
$278.20 mln (4 Analysts)
Q3 Adjusted EPS
Beat
$1.12
$0.78 (4 Analysts)
Q3 EPS
$0.78
Q3 Adjusted EBITDA
Beat
$131 mln
$102.70 mln (4 Analysts)
Q3 Adjusted Operating Income
Beat
$109.10 mln
$86.80 mln (4 Analysts)
Q3 Adjusted Gross Profit
$198.60 mln
Q3 Dividend
$0.15
Q3 Gross Profit
$197.10 mln
Q3 Operating Income
$94 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Embecta Corp is $18.00, about 42.4% above its August 7 closing price of $10.36

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release: ID:nGNXkNyb0

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)